Cancer · 1981 · 18 citations · 12 references
MedicineOncologyPharmacologyChemotherapyGenitourinary OncologyMedical OncologyAdjuvant ChemotherapyAdjuvant PharmacotherapyAdjuvant TherapyMalignant NeoplasmsTesticular CancerBiochemical RemissionChemotherapy Dose-limiting ToxicityDisease Stage AssessmentDose-limiting Toxicity AssessmentSerum Lactate MonitoringTesticular Cancer ChemotherapyTesticular Cancer Staging
Thirty-eight patients with nonseminomatous testicular cancer were treated with cis-platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twenty-Six patients with Stage III disease were treated. Seventy-six percent of those patients treated achieved complete remission. At a median survival time of 30 months, no patient who achieved a complete remission has relapsed. Twelve Stage II patients given adjuvant therapy remain free of disease at a median time of 23 months. Markedly elevated serum lactate dehydrogenase levels and massive disease were common findings in the patients who did not achieve complete remission. One drug death occurred secondary to sepsis. Symptoms of depression and anxiety were significant dose-limiting factors in this group of patients.
12
Effects of Combined Drug Therapy on Metastatic Cancer of the Testis
Min C. Li · JAMA · 1960 · 413 citations
Medicine, Oncology, Pharmacology +17
Surgical Management of Testis Tumor
William J. Staubitz, Kendall S. Early, Imre V. Magoss et al. · The Journal of Urology · 1974 · 117 citations
Germ cell tumors (II). VAB II in metastatic testicular cancer
Edgar Cheng, Esteban Cvitkovic, Robert E. Wittes et al. · Cancer · 1978 · 99 citations